Eliassen Eva, Krueger Gerhard, Luppi Mario, Ablashi Dharam
HHV-6 Foundation, Santa Barbara, California, USA.
Department of Pathology and Laboratory Medicine, University of Texas, Houston, Texas, USA.
Mediterr J Hematol Infect Dis. 2018 May 1;10(1):e2018035. doi: 10.4084/MJHID.2018.035. eCollection 2018.
Human herpesvirus 6A and 6B (HHV-6A and HHV-6B) have been noted since their discovery for their T-lymphotropism. Although it has proven difficult to determine the extent to which HHV-6A and HHV-6B are involved in the pathogenesis of many diseases, evidence suggests that primary infection and reactivation of both viruses may induce or contribute to the progression of several lymphoproliferative disorders, ranging from benign to malignant and including infectious mononucleosis-like illness, drug induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS), and nodular sclerosis Hodgkin's lymphoma. Herein, we discuss the conditions associated with the lymphoproliferative capacity of HHV-6, as well as the potential mechanisms behind them. Continued exploration on this topic may add to our understanding of the interactions between HHV-6 and the immune system and may open the doors to more accurate diagnosis and treatment of certain lymphoproliferative disorders.
人类疱疹病毒6A和6B(HHV - 6A和HHV - 6B)自发现以来就因其嗜T淋巴细胞特性而受到关注。尽管已证实难以确定HHV - 6A和HHV - 6B在许多疾病发病机制中的参与程度,但有证据表明,这两种病毒的初次感染和再激活可能诱导或促进多种淋巴增殖性疾病的进展,这些疾病范围从良性到恶性,包括传染性单核细胞增多症样疾病、药物性超敏反应综合征/伴有嗜酸性粒细胞增多和全身症状的药物反应(DIHS/DRESS)以及结节硬化型霍奇金淋巴瘤。在此,我们讨论与HHV - 6淋巴增殖能力相关的情况及其背后的潜在机制。对这一主题的持续探索可能会增进我们对HHV - 6与免疫系统之间相互作用的理解,并可能为某些淋巴增殖性疾病的更准确诊断和治疗打开大门。